ES2157248T3 - Uso de macrolidos para el tratamiento de isquemia cerebral. - Google Patents

Uso de macrolidos para el tratamiento de isquemia cerebral.

Info

Publication number
ES2157248T3
ES2157248T3 ES94903064T ES94903064T ES2157248T3 ES 2157248 T3 ES2157248 T3 ES 2157248T3 ES 94903064 T ES94903064 T ES 94903064T ES 94903064 T ES94903064 T ES 94903064T ES 2157248 T3 ES2157248 T3 ES 2157248T3
Authority
ES
Spain
Prior art keywords
pct
cerebral
hemorrhage
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903064T
Other languages
English (en)
Inventor
John S Kelly
Steven P Butcher
John Sharkey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2157248T3 publication Critical patent/ES2157248T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

EL PRESENTE INVENTO TRATA DE UN NUEVO USO DE LOS COMPUESTOS MACROLIDOS DE FORMULA (I), DONDE CADA SIMBOLO ES COMO ESTA DEFINIDO EN LA ESPECIFICACION, PARA PREVENIR O TRATAR LA ENFERMEDAD DE ISQUEMIA CEREBRAL. EL PRESENTE INVENTO OFRECE DROGAS UTILES PARA PREVENIR O TRATAR LA ENFERMEDAD DE LA ISQUEMIA CEREBRAL, EN OTRAS PALABRAS, UN DETERIORO CEREBRAL CAUSADO POR LA ISQUEMIA, COMO EL INFARTO CEREBRAL. POR LO TANTO, SON UTILES CUANDO SE TRATA DE LAS SIGUIENTES ENFERMEDADES O LESIONES: LESION DE CABEZA, DERRAME CEREBRAL COMO DERRAME SUB-ARACNOIDEO O DERRAME INTRACEREBRAL, TROMBOSIS CEREBRAL, EMBOLIA CEREBRAL, PARADA CARDIACA, INFARTO, ATAQUES ISQUEMICOS TRANSITORIOS (TIA), ENFALOPATIA HIPERTENSIVA, ETC.
ES94903064T 1992-12-29 1993-12-24 Uso de macrolidos para el tratamiento de isquemia cerebral. Expired - Lifetime ES2157248T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929227055A GB9227055D0 (en) 1992-12-29 1992-12-29 New use

Publications (1)

Publication Number Publication Date
ES2157248T3 true ES2157248T3 (es) 2001-08-16

Family

ID=10727284

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903064T Expired - Lifetime ES2157248T3 (es) 1992-12-29 1993-12-24 Uso de macrolidos para el tratamiento de isquemia cerebral.

Country Status (16)

Country Link
US (1) US5648351A (es)
EP (1) EP0676961B1 (es)
JP (1) JP3038920B2 (es)
KR (1) KR100299856B1 (es)
CN (1) CN1039622C (es)
AT (1) ATE201822T1 (es)
AU (1) AU687025B2 (es)
CA (1) CA2152803A1 (es)
DE (1) DE69330312T2 (es)
DK (1) DK0676961T3 (es)
ES (1) ES2157248T3 (es)
GB (1) GB9227055D0 (es)
GR (1) GR3036008T3 (es)
PT (1) PT676961E (es)
TW (1) TW291438B (es)
WO (1) WO1994014443A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6391899B1 (en) * 1998-07-17 2002-05-21 North Shore—Long Island Jewish Research Institute Compounds and compositions for treating tissue ischemia
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use
EP1223969A2 (en) * 1999-10-04 2002-07-24 Fujisawa Pharmaceutical Co., Ltd. Combined use of a plasminogen activator and il-2 inhibitors for neuroprotection
US20040147433A1 (en) * 2001-06-14 2004-07-29 Marcus Keep Neuroimmunophilins for selective neuronal radioprotection
JP2004323414A (ja) * 2003-04-24 2004-11-18 Japan Science & Technology Agency １４員環マクロライド化合物を利用した、血管平滑筋の増殖に起因する疾患治療剤
WO2008127746A1 (en) 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JP2799208B2 (ja) * 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
WO1991017754A1 (en) * 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Methods for treating and preventing inflammation of mucosa and blood vessels using fk 506 and related compounds
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity

Also Published As

Publication number Publication date
DE69330312T2 (de) 2001-10-11
EP0676961B1 (en) 2001-06-06
GR3036008T3 (en) 2001-09-28
HK1012229A1 (en) 1999-07-30
KR100299856B1 (ko) 2001-11-22
AU687025B2 (en) 1998-02-19
WO1994014443A1 (en) 1994-07-07
CN1039622C (zh) 1998-09-02
US5648351A (en) 1997-07-15
JP3038920B2 (ja) 2000-05-08
DK0676961T3 (da) 2001-09-10
CN1103580A (zh) 1995-06-14
TW291438B (es) 1996-11-21
EP0676961A1 (en) 1995-10-18
GB9227055D0 (en) 1993-02-24
ATE201822T1 (de) 2001-06-15
PT676961E (pt) 2001-10-30
JPH08505136A (ja) 1996-06-04
AU5716094A (en) 1994-07-19
CA2152803A1 (en) 1994-07-07
KR960700055A (ko) 1996-01-19
DE69330312D1 (de) 2001-07-12

Similar Documents

Publication Publication Date Title
BR9714272A (pt) Taxóide, composição farmacêutica tendo atividade de inversão de resistência a medicamento, e, processo para tratar tumores
DE60226881D1 (de) High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
PA8503301A1 (es) Compuestos para el tratamiento de la isquemia
BR9407812A (pt) Compostos uso e processo de preparação dos mesmos composições farmacêuticas uso das mesmas e processo de tratamento de ataques distúrbios neurológicos e/ou condições nas quais há dano neurológico nos animais incluindo seres humanos
ES2089600T3 (es) Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas.
RU94037964A (ru) Производные 1-амино-этилиндола
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
RU95112484A (ru) Производные 2,3,4,5-тетрагидро-1,4-бензотиазепинов, фармацевтическая композиция, способ лечения неврологических расстройств, припадков, способ защиты нервной системы, способ получения, использование
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
TNSN04100A1 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof , the use thereof as medicaments, in addition to a medicament containing same
DK0676961T3 (da) Anvendelse af macrolider til behandling af cerebral iskæmi
NO930143D0 (no) Piperidinforbindelser, deres fremstilling og bruk
ATE245447T1 (de) Inhibitor von gehirnödemen
BR9406577A (pt) Compostos uso dos mesmos processo para a preparação dos mesmos e processo para neuroproteção ou para tratamento da depressão ansiedade doença de parkinson obesidade distúrbios cognitivos ataques e distúrbios neurológicos
BR0212967A (pt) Composição de limpeza, uso da mesma, e, processos para limpar tecido sujo ou mobìlias macias, e, superfìcies duras sujas
DK1557414T3 (da) IsoquinoIin-forbindelser og medicinsk anvendelse deraf
DE69309297D1 (de) Neuroprotektive 3,4-dihydro-2(1h)-chinolone
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
DE60104435D1 (en) 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel
KR980000445A (ko) 인식 증강 방법
AR021463A1 (es) Antibiotico de piridona con perfil de seguridad mejorado
BR0108193A (pt) Processo para tratamento ou inibição de dano celular ou morte celular
DE69418689D1 (de) Nitrone verwendbar zum abfangen von freien radikalen
WO2002028388A3 (en) Use of mek1 inhibitors as protective agents against damage due to ischemia
ATE215824T1 (de) Mittel zur verminderung des augeninnendrucks

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 676961

Country of ref document: ES